The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
eVOLVE-HNSCC: A global phase 3 study of volrustomig as sequential therapy for unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) following definitive concurrent chemoradiotherapy (cCRT).
 
Robert I. Haddad
Employment - Dana-Farber Cancer Institute
Leadership - NCCN
Stock and Other Ownership Interests - tosk
Consulting or Advisory Role - ALX Oncology; AstraZeneca; aveo; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Coherus Biosciences; Eisai; EMD Serono; Galera Therapeutics; Genmab; GlaxoSmithKline; Merck; Merus; PDS Biotechnology; Scholar Rock
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genentech (Inst); Incyte (Inst); Kura Oncology (Inst); Merck (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Other Relationship - Boehringer Ingelheim; Hookipa Pharma; ISA Pharmaceuticals; Nanobiotix
 
Dario Ruscica
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Alexandra Visa
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Xia Li
Employment - AstraZeneca
 
Lisa F. Licitra
Honoraria - Adlai Nortye; ALTIS Omnia Pharma Service S.r.l.; Bristol Mayers Squibb [K.K.]; Merck KGaA; Merck Serono; MSD IT
Consulting or Advisory Role - Abbvie S.r.l.; ALX Oncology; AstraZeneca; Boehringer Ingelheim; Eisai; EMD Ser Reaserach & Development Institute Inc.; Genmab; GlaxoSmithKline; GroupH Ltd; Janssen Research & Development; Merck Healtcare KGaA; Merck Serono; Mirati Therapeutics; MSD; MSD; Novartis Farma S.p.a.; Roche; Seagan
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Debiopharm Group (Inst); Eisai (Inst); Exelixis (Inst); IRX Therapeutics (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - TAE Life Sciences